GuangYuYuan(SH:600771)2020-10-30 16:00Financial Performance - Net profit attributable to shareholders of the listed company was CNY 64,842,641.70, a decrease of 62.69% year-on-year[9]. - Operating revenue for the period was CNY 686,946,143.57, down 19.58% from the same period last year[9]. - The weighted average return on net assets decreased to 2.71%, down 4.69 percentage points from the previous year[9]. - Basic earnings per share were CNY 0.13, a decline of 62.86% compared to CNY 0.35 in the previous year[9]. - Total profit decreased by CNY 149.37 million, a decline of 69.54%, primarily due to a 19.58% decrease in sales revenue impacted by the COVID-19 pandemic[28]. - Net profit decreased by CNY 119.96 million, a decline of 65.45%, attributed to increased marketing and advertising expenses[28]. - Net profit for Q3 2020 was approximately ¥20.61 million, compared to ¥59.13 million in Q3 2019, indicating a decline of 65.06%[63]. - The total comprehensive income for Q3 2020 was approximately ¥20.61 million, a decrease of 65.06% from ¥59.13 million in Q3 2019[66]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,902,020,278.76, an increase of 10.31% compared to the end of the previous year[9]. - Total liabilities increased to ¥1,399,406,473.43 from ¥1,095,580,771.58, reflecting a growth of approximately 28%[43]. - Owner's equity attributable to shareholders rose to ¥2,421,779,060.77 from ¥2,356,936,419.07, an increase of about 3%[46]. - Total non-current assets amounted to ¥950,445,557.66, unchanged from the previous period[95]. - Current liabilities totaled ¥1,056,147,465.83, with short-term borrowings at ¥173,427,800.00[98]. - The total equity of the company stands at 2,757,215,951.38, with an accumulated deficit of -581,890,616.30[112]. Cash Flow - Net cash flow from operating activities was CNY -163,450,467.38, compared to CNY -128,679,933.87 in the same period last year[9]. - Cash flow from operating activities for the first three quarters of 2020 was negative CNY 163,450,467.38, compared to negative CNY 128,679,933.87 in the same period of 2019[78]. - The total cash inflow from operating activities was ¥877,949,411.22, significantly higher than ¥445,772,491.35 in the previous year, indicating a growth of 96.8%[85]. - The company experienced a net cash outflow from investment activities of ¥33,233,750.99, compared to a smaller outflow of ¥26,095.18 in 2019[87]. - Cash flow from financing activities showed a net inflow of ¥123,138,211.41, down from ¥207,040,392.92 in the previous year, reflecting a decrease of 40.5%[88]. Shareholder Information - The total number of shareholders at the end of the reporting period was 32,369[12]. - The top shareholder, Xi'an Dongsheng Group Co., Ltd., held 63,693,726 shares, accounting for 12.95% of the total shares[12]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 22,977,411.34 from the beginning of the year to the end of the reporting period[12]. - The company reported a total non-operating income and expenses of CNY 18,651,542.92 for the year-to-date[12]. - The company reported other income of CNY 533,355.56 in Q3 2020, significantly higher than CNY 40,704.00 in Q3 2019[71]. Investments and Expenditures - Development expenditures increased by CNY 14.22 million, a growth of 299.55%, mainly due to increased investment in clinical efficacy and pharmacology for specific products[25]. - Long-term equity investments increased to ¥7,752,568.66 from ¥6,266,889.38, a growth of approximately 24%[40]. - Other equity instrument investments rose to ¥22,350,000.00 from ¥17,350,000.00, reflecting a 29% increase[40]. Changes in Accounting and Financial Standards - The company implemented a new revenue recognition standard starting January 1, 2020, adjusting prepayments to contract liabilities[101]. - The company has adjusted its financial statements to reflect the new revenue recognition standards effective from January 1, 2020, moving prepayments to contract liabilities[113].